Coordinated by GU Ventures
GU Ventures welcomes Fredrik Wångsell as Business Development Manager
We are pleased to announce that Fredrik Wångsell joined the team this fall as a Business Developer within Life Science, with a primary focus on New Modality Support (NMS), a forward-looking initiative in collaboration with the Sahlgrenska Academy, the medical faculty at the University of Gothenburg, and the Sahlgrenska University Hospital. The aim is to support the commercial development of research projects within the national pharmaceutical initiatives OligoNova and CCRM Nordic.
Fredrik shares his role as a Business Developer at GU Ventures with his position as a Research Advisor at the OligoNova Hub within the SciLifeLab Drug Discovery and Development (DDD) platform. Fredrik holds a Ph.D. in Pharmacy from Uppsala University and has over 15 years of industry experience in research and development within small and medium-sized enterprises.
Throughout his career, he has held leadership positions with responsibilities for early drug development and early-phase clinical trials. He has combined his passion for translating early innovations into commercial value, focusing on drug development, translational science, IND-enabling, and preclinical toxicological evaluation to support clinical development.
- “I have a broad interest in drug development, new innovations, and technology advancement. For me, it’s fascinating to follow a project’s journey toward becoming a product that can benefit patients. Therefore, I am thrilled to be a part of the NMS team and the development of Swedish Life Science. In this way, I can contribute to shaping and developing the medicines and companies of the future with the support of GU Ventures,” says Fredrik.
In addition to his deep expertise and competence, Fredrik is a highly engaged and curious person who is attentive and motivated to help new innovations reach practical application. He is passionate about exploring various fields and taking on new challenges. Furthermore, he enjoys meeting and working with new people and connecting them with his colleagues as well as with researchers supported within the OligoNova Hub.
GU Ventures welcomes Fredrik to the team
Colleagues at GU Ventures are delighted to welcome Fredrik to the team and look forward to a long and rewarding collaboration.
- “I would like to warmly welcome Fredrik to GU Ventures! It is fantastic that we can share his expertise with the OligoNova Hub. For us, it is crucial to leverage Fredrik’s specialized knowledge and network in the NMS project, and at the same time, we are delighted that he can also support us in business development at GU Ventures. We have already had the opportunity to work with Fredrik since he joined the OligoNova Hub, and our entire team appreciates him both for his work style and as a highly knowledgeable colleague.”, says Carl-Peter Mattsson, Investment Director at GU Ventures and Strategic Coordinator for NMS.
For additional information, please contact:
Carl-Peter Mattsson, Investment Director, GU Ventures
Phone: +46(0)708699354
Email: carl-peter@ventures.gu.se
About New Modality Support (NMS)
NMS supports the further development and commercialization of individual research projects within the therapeutic oligonucleotide and ATMP sectors. By combining the experience and resources of participating parties with new, sector-specific expertise, value-creating services can be developed and deployed more efficiently. Additionally, as a platform that promotes networking and highlights both the research and commercialization efforts, NMS enhances opportunities for projects and companies to attract investments and partnerships.
NMS is located at GoCo Health Innovation City in Mölndal and is supported by both the Västra Götaland Region through the Environment and Regional Development Board, as well as by the University of Gothenburg and GU Ventures. This support enables GU Ventures, the coordinator for NMS, to work strategically and sustainably towards the project´s success.
For more information, please visit:
